<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342300</url>
  </required_header>
  <id_info>
    <org_study_id>CBTRA-03</org_study_id>
    <nct_id>NCT03342300</nct_id>
  </id_info>
  <brief_title>Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma</brief_title>
  <acronym>PDVPSTS</acronym>
  <official_title>Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine, a Multicentre, Open-label, Randomised Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Shougang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still
      benefit from doxorubicin, ifosfamide and dacarbazine. However doxorubicin might be stopped
      using because of chronic cumulative heart toxicity. Several efforts have been made to improve
      the toxicity profile of conventional anthracyclines, including the use of liposomal
      encapsulation technology and the development of novel anthracycline analogs,such as pegylated
      liposomal doxorubicin and pirarubicin. However their actual effectiveness and toxicity have
      not been studied in prospective trial. The purpose of the study is to investigate whether
      they are available for this group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We design this multicentre, open-label, randomised, phase 2 trial at 5 academic hospitals in
      China. Eligible patients need to be aged 16 years or older with a diagnosis of an advanced
      unresectable or metastatic soft-tissue sarcoma, of intermediate or high grade, for which no
      standard curative therapy will be available, an Eastern Cooperative Oncology Group
      performance status of 0-1, and measurable disease by Response Evaluation Criteria in Solid
      Tumors version 1.1.

      Participants will be randomly assigned (1:1) to receive pegylated liposomal doxorubicin (60
      mg/m² via continuous intravenous infusion for 4-6 h on day 1 of every 21-day cycle for up to
      six cycles) or pirarubicin (30 mg/m2/d continuous intravenous infusion for 3h on day 1 and 2
      of every 21-day cycle for up to six cycles) plus ifosfamide ( 2 g/m²/d intravenously for 2h
      on day 2,3 and 4 of every 21-day cycle for up to six cycles), dacarbazine (300 mg/m²/d
      intravenously for 2h on day 2,3 and 4 of every 21-day cycle for up to six cycles ).After six
      cycles of treatment, patients will be followed up expectantly whereas patients with stable or
      responsive disease are allowed to continue with ifosfamide and dacarbzine until documented
      disease progression. A web-based central randomisation with block sizes of two and four was
      stratified by extent of disease, drug administration method, and previous systemic therapy.
      Patients and investigators will not be masked to treatment assignment. The primary endpoint
      is progression survival, analysed in the intention-to-treat population. Safety analyses will
      be done in all patients who receive any amount of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned (1:1) to receive pegylated liposomal doxorubicin (50 mg/m² on day 1 of every 21-day cycle for up to six cycles) or pirarubicin (60 mg/m² on day 1 of every 21-day cycle for up to six cycles) plus ifosfamide (2 g/m²/d d2-4 of every 21-day cycle for up to six cycles) and dacarbazine (300 mg/m²/d d2-4 of every 21-day cycle for up to six cycles).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>A web-based central randomisation with block sizes of two and four was stratified by extent of disease,anthracycline administration method, and previous systemic therapy. Participants and investigators will not be masked to treatment assignment. The primary endpoint will be assessed in the intention-to-treat population. The outcome assessors will be masked to the two research groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>12 weeks</time_frame>
    <description>Progression-free survival is defined as time from randomisation to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment or randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>overall survival is defined as the duration from date of randomisation to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate, ORR</measure>
    <time_frame>12 weeks</time_frame>
    <description>objective response rate includes complete and partial responses as defined by RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular ejection fraction function</measure>
    <time_frame>12 months</time_frame>
    <description>We use ultrasound to routinely estimate the left ventricular ejection fraction function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Progression-free Survival</condition>
  <condition>Overall Survival</condition>
  <condition>Toxicity</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin</intervention_name>
    <description>Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirarubicin</intervention_name>
    <description>Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16 years or older;

          -  diagnosis of an advanced unresectable or metastatic soft tissue sarcoma, of
             intermediate or high grade, for which no standard curative therapy is available;

          -  cumulative dose of anthracycline antibiotic ≥ 300mg/m2;

          -  stable or responsive to doxorubicin, potential beneficiary;

          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, a life
             expectancy of at least 3 months;

          -  measurable disease according to RECIST 1.1;

          -  adequate end-organ and haemopoietic function.

        Exclusion Criteria:

          -  progress over doxorubicin;

          -  previous mediastinal or cardiac radiotherapy;

          -  a low-grade tumour according to standard grading systems (eg, American Joint Committee
             on Cancer grade 1 and 2 or Fédération Nationale des Centres de Lutte Contre le Cancer
             grade 1);

          -  significant cardiac dysfunction;

          -  severe chronic obstructive pulmonary disease;

          -  a known infection with HIV or active infection with hepatitis B or hepatitis C;

          -  known brain metastases unless previously treated and well controlled for a period of 3
             months or longer;

          -  combination with other anti-tumor therapy;

          -  pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Guo, M.D.and Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Musculoskeletal Tumor Center of Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Xie, M.D.</last_name>
    <phone>+86-13401044719</phone>
    <email>sweetdoctor@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Xu, M.D.</last_name>
    <phone>+86-15901040835</phone>
    <email>xujie_pkuph@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tingting Ren, Ph.D.</last_name>
      <phone>+86-13810095026</phone>
      <email>tumorcenter@163.com</email>
    </contact>
    <investigator>
      <last_name>Wei Guo, M.D. and Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017 Jun 2;15(1):109. doi: 10.1186/s12916-017-0872-y. Review.</citation>
    <PMID>28571564</PMID>
  </reference>
  <reference>
    <citation>Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276-85.</citation>
    <PMID>8315425</PMID>
  </reference>
  <reference>
    <citation>Jelić S, Kovcin V, Milanović N, Babović N, Kreacić M, Ristović Z, Vlajić M, Filipović-Ljesković I. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer. 1997 Feb;33(2):220-5.</citation>
    <PMID>9135492</PMID>
  </reference>
  <reference>
    <citation>Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676-84.</citation>
    <PMID>10894866</PMID>
  </reference>
  <reference>
    <citation>Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537-45.</citation>
    <PMID>7602342</PMID>
  </reference>
  <reference>
    <citation>Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464.</citation>
    <PMID>27291997</PMID>
  </reference>
  <reference>
    <citation>Bui-Nguyen B, Butrynski JE, Penel N, Blay JY, Isambert N, Milhem M, Kerst JM, Reyners AK, Litière S, Marréaud S, Collin F, van der Graaf WT; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC/STBSG) and the Sarcoma Alliance for Research through Collaboration (SARC). A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer. 2015 Jul;51(10):1312-20. doi: 10.1016/j.ejca.2015.03.023. Epub 2015 Apr 23.</citation>
    <PMID>25912752</PMID>
  </reference>
  <reference>
    <citation>Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.</citation>
    <PMID>21937277</PMID>
  </reference>
  <reference>
    <citation>Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302-14.</citation>
    <PMID>4353012</PMID>
  </reference>
  <reference>
    <citation>Vondráková D, Málek F, Ošťádal P, Vránová J, Miroslav P, Schejbalová M, Neužil P. Correlation of NT-proBNP, proANP and novel biomarkers: copeptin and proadrenomedullin with LVEF and NYHA in patients with ischemic CHF, non-ischemic CHF and arterial hypertension. Int J Cardiol. 2011 Aug 4;150(3):343-4. doi: 10.1016/j.ijcard.2011.05.029. Epub 2011 Jun 2.</citation>
    <PMID>21640398</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710-7.</citation>
    <PMID>496103</PMID>
  </reference>
  <reference>
    <citation>Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8. doi: 10.4103/0973-1482.139267. Review.</citation>
    <PMID>25579518</PMID>
  </reference>
  <reference>
    <citation>Nielsen OS, Dombernowsky P, Mouridsen H, Daugaard S, Van Glabbeke M, Kirkpatrick A, Verweij J. Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group. Sarcoma. 2000;4(1-2):31-5. doi: 10.1155/S1357714X00000062.</citation>
    <PMID>18521432</PMID>
  </reference>
  <reference>
    <citation>Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001 May;37(7):870-7.</citation>
    <PMID>11313175</PMID>
  </reference>
  <reference>
    <citation>Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, Kosmidis P, Fountzilas G, Gogas H, Kalofonos C, Dimopoulos AM. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Br J Cancer. 2004 Nov 1;91(9):1639-44.</citation>
    <PMID>15494721</PMID>
  </reference>
  <reference>
    <citation>Poveda A, López-Pousa A, Martín J, Del Muro JG, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM. Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma. 2005;9(3-4):127-32. doi: 10.1080/13577140500287024.</citation>
    <PMID>18521419</PMID>
  </reference>
  <reference>
    <citation>Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002 Mar;38(4):543-9.</citation>
    <PMID>11872347</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>pegylated liposomal doxorubicin</keyword>
  <keyword>pirarubicin</keyword>
  <keyword>toxicity for heart</keyword>
  <keyword>cumulative dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

